TD Cowen lowered the firm’s price target on Ultragenyx (RARE) to $49 from $75 and keeps a Buy rating on the shares. Given growing uncertainty about the FDA’s stance on bio-marker based approvals for drugs treating rare diseases, the firm sees regulatory risk having increased for UX111 and it also notes that the company’s 2026 revenue forecast fell short of consensus estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: